Skip to main content
. Author manuscript; available in PMC: 2018 Feb 13.
Published in final edited form as: Adv Healthc Mater. 2015 Mar 13;5(1):10–55. doi: 10.1002/adhm.201400842

Figure 13.

Figure 13

Mesenchymal stem cells genetically engineered to secrete TRAIL to enhance the treatment of glioma. A–F) Serial in vivo bioluminescence imaging of tumor growth following intracranial implantation of Gli36-EGFRvIII-FD glioma cells mixed with MSCs expressing S-TRAIL (MSC-S-TRAIL; B,D,F) or GFP (MSC-GFP; A,C,E). G) Relative mean bioluminescent signal intensities after quantification of in vivo images. H–M) Photomicrographs show the presence of cleaved caspase-3 (H) and Ki67-positive cells (K) in brain sections from MSC-S-TRAIL-treated and control mice (I,L) 6 days after implantation. Plot shows the number of cleaved caspase-3 (J) and Ki67 (M) cells in MSC-S-TRAIL and MSC-GFP-treated tumors. (Green, MSCs; red, glioma cells; purple, Ki67 or cleaved caspase-3 expression). Reproduced with permission.[265] Copyright 2009, PNAS.